NASDAQ:IART

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART

Retrieved on: 
Wednesday, March 27, 2024
Pomerantz, Prior, LLP

NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQ: IART) (“Integra”) potentially breached their fiduciary duties to shareholders.

Key Points: 
  • NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQ: IART) (“Integra”) potentially breached their fiduciary duties to shareholders.
  • Please contact us for more information if you have continuously owned shares of Integra Lifesciences Holdings Corp since January 2023.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term Investors to Contact the Firm

Retrieved on: 
Wednesday, February 14, 2024
Complaint, Acquisition, Integra, Boston, FDA, Lipopolysaccharide, Management control system, Pharmaceutical industry

PHILADELPHIA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company’s long-term investors.
  • After receiving the 2018 Form 483, Integra issued a series of responses purporting to address the problems identified by the FDA.
  • Integra shareholders who purchased or acquired their shares prior to April 26, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.

INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Telephone, Letter, FDA, Lipopolysaccharide, Complaint, Integra, P.C, Infection, Patient, PMA

Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company.
  • In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
  • Consequently, on November 2, 2018, the FDA issued a Notice of Inspectional Observations on Form 483 (the “2018 Form 483”) to put Integra on notice of those violations.
  • Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.

DEADLINE ALERT for DOCN, IART, and EVA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, November 13, 2023
Defendant, EBITDA, PMA, Suite, Integra, Law, Complaint, Investment, DigitalOcean, FDA, Security (finance), Enviva

LOS ANGELES, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Integra LifeSciences Holdings Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 13, 2023 – (NASDAQ: IART)

Retrieved on: 
Monday, November 13, 2023
NEXT, Fraud, Integra, PMA, FDA, Holding company, Security (finance)

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation.
  • Shareholders who purchased shares of IART during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: November 13, 2023 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

IART 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Integra LifeSciences (IART) Investors with Substantial Losses to Contact the Firm Before Nov. 13th Deadline in Securities Fraud Class Action

Retrieved on: 
Saturday, November 11, 2023
SAN, Lipopolysaccharide, Person, EPS, FDA, Good manufacturing practice, Hagens Berman, PMA, Pharmaceutical industry, Life insurance, Integra, Boston

SAN FRANCISCO, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .
  • Integra LifeSciences Holdings Corp. (IART) Securities Fraud Class Action:
    The litigation focuses on Integra’s disclosures related to the FDA’s findings of Good Manufacturing Practices violations at its Boston Facility.
  • 26, 2023, when Integra revealed that it paused production at the Boston Facility.
  • “We’re focused on investors’ losses and whether Integra misled investors about its compliance with worldwide Good Manufacturing Practices,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

INTEGRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Integra To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, November 9, 2023
Lipopolysaccharide, LLP, Advertising, Patient, Woman, Infection, FDA, Boston, Failure, Court, PMA, Cryptocurrency, Dietary supplement, Pharmaceutical industry, Integra

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) and reminds investors of the November 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
  • Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Integra’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation (IART) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, November 9, 2023
Telephone, LLP, FDA, CLASS, NEXT, Court, PMA, COST, Integra

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    IART investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Friday, November 10, 2023
Class Action Lawsuit, Professional Services, Legal, Defendant, PMA, Suite, Integra, Law, Lipopolysaccharide, FDA, Court, News, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART ) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART ) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INTEGRA LIFESCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Integra LifeSciences Holdings Corporation - IART

Retrieved on: 
Friday, November 10, 2023
Class Action Lawsuit, Professional Services, Legal, Integra, Lipopolysaccharide, District court, Firefighter, Court, News, Special warfare combatant-craft crewmen, KSF

This action is pending in the United States District Court for the District of New Jersey.

Key Points: 
  • This action is pending in the United States District Court for the District of New Jersey.
  • Integra and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • The case is Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.